News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

1HP safe, feasible for tuberculosis prevention in exposed individuals without HIV
12 Mar 2026
byStephen Padilla
Treatment with isoniazid and rifapentine (HP) either for 1 month daily (1HP) or 3 months weekly (3HP) results in high rates of treatment success among people with a positive latent tuberculosis infection test and without HIV infection, a study has shown. The 3HP regimen has slightly lower rates of adverse reactions, but neither exhibits superiority to the other.
1HP safe, feasible for tuberculosis prevention in exposed individuals without HIV
12 Mar 2026
RW data support enfortumab vedotin-pembrolizumab combo as 1L Tx for bladder cancer
12 Mar 2026
byAudrey Abella
Real-world (RW) data presented at ASCO GU 2026 support the use of enfortumab vedotin plus pembrolizumab (EV+P) as frontline treatment for advanced urothelial carcinoma (UC).
RW data support enfortumab vedotin-pembrolizumab combo as 1L Tx for bladder cancer
12 Mar 2026
Air pollution ups risk of Alzheimer’s disease
11 Mar 2026
byStephen Padilla
Exposure to fine particulate matter PM2.5 may elevate the risk for Alzheimer’s disease (AD), mainly through direct pathways instead of mediation by common comorbidities, suggests a study.






